Literature DB >> 17252614

Immortal time bias in observational studies of drug effects.

Samy Suissa1.   

Abstract

PURPOSE: Recent observational studies suggest that various drugs are remarkably effective at reducing morbidity and mortality. These cohort studies used a flawed approach to design and data analysis which can lead to immortal time bias. We describe the bias from 20 of these studies and illustrate it by showing that unrelated drugs can be made to appear effective at treating cardiovascular disease (CVD).
METHODS: The illustration used a cohort of 3315 patients, with chronic obstructive pulmonary disease (COPD), identified from the Saskatchewan Health databases, hospitalised for CVD and followed for up to a year. We used the biased approach to assess the effect of two medications, namely gastrointestinal drugs (GID) and inhaled beta-agonists (IBA), both unknown to be effective in CVD, on the risk of all-cause mortality. We also estimated these effects using the proper person-time approach.
RESULTS: Using the inappropriate approach, the rates ratios of all-cause death were 0.73 (95%CI: 0.57-0.93), with IBA and 0.78 (95%CI: 0.61-0.99), with GID. These rate ratios became 0.98 (95%CI: 0.77-1.25) and 0.94 (95%CI: 0.73-1.20), respectively, with the proper person-time analysis.
CONCLUSIONS: Several recent observational studies used a flawed approach to design and data analysis, leading to immortal time bias, which can generate an illusion of treatment effectiveness. Observational studies, with surprising beneficial drug effects should be re-assessed to account for this source of bias. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17252614     DOI: 10.1002/pds.1357

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  128 in total

1.  Counterpoint: the treatment decision design.

Authors:  M Alan Brookhart
Journal:  Am J Epidemiol       Date:  2015-10-26       Impact factor: 4.897

2.  The role of matching when adjusting for baseline differences in the outcome variable of comparative effectiveness studies.

Authors:  Carlos G Grijalva; Christianne L Roumie; Harvey J Murff; Adriana M Hung; Cole Beck; Xulei Liu; Marie R Griffin; Robert A Greevy
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

Review 3.  Mortality benefit from unrestricted access to clopidogrel: too good to be true?

Authors:  Samy Suissa
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

4.  Myocardial infarction risk among patients with fractures receiving bisphosphonates.

Authors:  Cory B Pittman; Lisa A Davis; Angelique L Zeringue; Liron Caplan; Kent R Wehmeier; Jeffrey F Scherrer; Hong Xian; Francesca E Cunningham; Jay R McDonald; Alexis Arnold; Seth A Eisen
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

5.  The landscape of comparative effectiveness research in rheumatology.

Authors:  Esi Morgan DeWitt; Hermine I Brunner
Journal:  Nat Rev Rheumatol       Date:  2013-09-24       Impact factor: 20.543

6.  Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants.

Authors:  Jonathan L Slaughter; Patricia B Reagan; Thomas B Newman; Mark A Klebanoff
Journal:  JAMA Pediatr       Date:  2017-03-06       Impact factor: 16.193

7.  Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.

Authors:  Nisha Bansal; Adam Szpiro; Kristi Reynolds; David H Smith; David J Magid; Jerry H Gurwitz; Frederick Masoudi; Robert T Greenlee; Grace H Tabada; Sue Hee Sung; Ashveena Dighe; Alan S Go
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

8.  Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.

Authors:  Janick Weberpals; Lina Jansen; Myrthe P P van Herk-Sukel; Josephina G Kuiper; Mieke J Aarts; Pauline A J Vissers; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2017-09-01       Impact factor: 8.082

9.  Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies.

Authors:  Ayumi K Shintani; Timothy D Girard; Svetlana K Eden; Patrick G Arbogast; Karel G M Moons; E Wesley Ely
Journal:  Crit Care Med       Date:  2009-11       Impact factor: 7.598

10.  The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.

Authors:  Lauren P Wallner; Julia R DiBello; Bonnie H Li; Stephen K Van Den Eeden; Sheila Weinmann; Debra P Ritzwoller; Jill E Abell; Ralph D'Agostino; Ronald K Loo; David S Aaronson; Ralph I Horwitz; Steven J Jacobsen
Journal:  Urology       Date:  2018-06-12       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.